Is Lyra Therapeutics, Inc. (LYRA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1515.3% / 30% | 1788.5% / 30% | 0.0% / 30% | 192.44% / 5% | ✗ NOT HALAL |
| DJIM | 1515.3% / 33% | 1788.5% / 33% | 0.0% / 33% | 192.44% / 5% | ✗ NOT HALAL |
| MSCI | 51.8% / 33% | 61.2% / 33% | 0.0% / 33% | 192.44% / 5% | ✗ NOT HALAL |
| S&P | 1515.3% / 33% | 1788.5% / 33% | 0.0% / 33% | 192.44% / 5% | ✗ NOT HALAL |
| FTSE | 51.8% / 33% | 61.2% / 33% | 0.0% / 50% | 192.44% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -25032.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -404.5% | |
| Return on Assets (ROA) | -33.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$70M |
| Free Cash Flow | -$72M |
| Total Debt | $34M |
| Current Ratio | 2.4 |
| Total Assets | $66M |
Price & Trading
| Last Close | $0.49 |
| 50-Day MA | $1.36 |
| 200-Day MA | $4.90 |
| Avg Volume | 110K |
| Beta | 0.1 |
|
52-Week Range
$0.31
| |
About Lyra Therapeutics, Inc. (LYRA)
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Lyra Therapeutics, Inc. (LYRA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Lyra Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Lyra Therapeutics, Inc.'s debt ratio?
Lyra Therapeutics, Inc.'s debt ratio is 1515.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 51.8%.
What are Lyra Therapeutics, Inc.'s key financial metrics?
Lyra Therapeutics, Inc. has a market capitalization of $870,047, and revenue of $2M. Return on equity stands at -404.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.